Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship

James A. Cook, F. Christopher Zusi, Ivar M. McDonald, Dalton King, Matthew D. Hill, Christiana Iwuagwu, Robert Mate, Haiquan Fang, Bei Wang, Jingfang Cutrone,

Journal of Medicinal Chemistry · 2016 · 18 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

The design and synthesis of a series of quinuclidine-containing spirooxazolidines (“spiroimidates”) and their utility as α7 nicotinic acetylcholine receptor partial agonists are described. Selected members of the series demonstrated excellent selectivity for α7 over the highly homologous 5-HT 3A receptor. Modification of the N -spiroimidate heterocycle substituent led to (1 S,2 R,4 S )- N -isoquinolin-3-yl)-4′ H -4-azaspiro[bicyclo[2.2.2]octane-2,5′oxazol]-2′-amine (BMS-902483), a potent α7 partial agonist, which improved cognition in preclinical rodent models.

References

32